Renal Cell Carcinoma Drug May Help Fight Papillary Thyroid Cancer

by: cancercompass

A drug used to treat advanced renal cell carcinoma was tolerated well in papillary thyroid cancer patients during its Phase II trial, according to study results published in the March online edition of the Journal of Clinical Oncology.

Sorafenib, known as Nexavar, is FDA-approved to treat an advanced stage of kidney cancer called renal cell carcinoma. This recent study says the drug may also help fight papillary thyroid cancer.

Ohio State University Researchers assessed bi-monthly responses in 41 papillary thyroid cancer patients assigned 400 mg of sorafenib twice per day.  Patients were split into two groups: Arm A, which required a tumor for biopsy, and Arm B, who had subtypes of carcinoma and didn't require tumor biopsy.

Overall study findings concluded that 23 of the 41 patients had a stable disease condition for longer than six months. Median progression-free survival was 15 months.  Common side effects were fatigue, musculoskeletal pain and hand-foot skin reaction.

Cancer drugs and surgery are common thyroid cancer treatments, though other options do exist. Learn more about thyroid cancer treatment.